Ardelyx (ARDX) Return on Capital Employed (2014 - 2026)
Ardelyx's (ARDX) quarterly Return on Capital Employed came in at 9.51% in Q1 2026, up 190.0% YoY from 3.28% in Q1 2025, and up 5.94% on a QoQ basis from 10.11% in Q4 2025.
Ardelyx (ARDX) Return on Capital Employed (2014 - 2026) Analysis & Trends
Ardelyx (ARDX) has 13 years of Return on Capital Employed data on file, last reported at 9.51% in Q1 2026.
- Quarterly Return on Capital Employed rose 190.0% year-over-year to 9.51% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 9.51% (up 190.0% YoY) and the FY2025 annual result came in at 10.78%, down 110.0% from the prior year.
- Return on Capital Employed climbed to 9.51% in Q1 2026, from 10.11% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 8.63% in Q4 2024 to a low of 163.53% in Q1 2022.
- A 5-year average of 44.67% and a median of 22.46% in 2024 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2022 — Return on Capital Employed slumped 10199 bps — and 2023, when it soared 12638 bps.
- Tracing ARDX's Return on Capital Employed over 5 years: stood at 62.65% in 2022, then jumped by 58 bps to 26.03% in 2023, then surged by 67 bps to 8.63% in 2024, then declined by 17 bps to 10.11% in 2025, then gained by 6 bps to 9.51% in 2026.
- The last three Return on Capital Employed figures came in at 9.51% (Q1 2026), 10.11% (Q4 2025), and 9.65% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Ardelyx | 1.01 Bn | 729.71 Mn | 115.12 Mn | -8.69% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -8.69% |
| Mar 31, 2026 | -9.51% |
| Dec 31, 2025 | -10.11% |
| Sep 30, 2025 | -9.65% |
| Jun 30, 2025 | -11.32% |
| Mar 31, 2025 | -11.41% |
| Dec 31, 2024 | -8.63% |
| Sep 30, 2024 | -22.46% |
| Jun 30, 2024 | -21.00% |
| Mar 31, 2024 | -23.52% |
| Dec 31, 2023 | -26.03% |
| Sep 30, 2023 | -11.19% |
| Jun 30, 2023 | -34.39% |
| Mar 31, 2023 | -44.15% |
| Dec 31, 2022 | -62.65% |
| Sep 30, 2022 | -128.99% |
| Jun 30, 2022 | -160.78% |
| Mar 31, 2022 | -163.53% |
| Dec 31, 2021 | -143.50% |
| Sep 30, 2021 | -123.14% |